読み込み中
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
前日終値
$4.65
+$0.19 · +4.26%
日中の時刻はETです。市場データは遅延する場合があります。
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
日中レンジ
現在 $4.65
52週レンジ
現在 $4.65
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
37
割高
センチメント
65
強気
リスク
56
やや高いリスク
モメンタム
52
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
日中レンジ
現在 $4.65
52週レンジ
現在 $4.65
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1419.6万 USD | 1099.2万 USD | 1904.9万 USD | 3985万 USD | 58.9万 USD |
| 粗利益 | 1419.6万 USD | 1099.2万 USD | 1904.9万 USD | 3985万 USD | 58.9万 USD |
| 研究開発 | 3081.2万 USD | 2685.1万 USD | 1765.3万 USD | 1435.5万 USD | 1517.3万 USD |
| 販売・一般管理 | 2198.3万 USD | 1821.5万 USD | 1195.9万 USD | 726.9万 USD | 812.1万 USD |
| 営業費用 | 5279.5万 USD | 7306.6万 USD | 2961.2万 USD | 2162.4万 USD | 2329.4万 USD |
| 支払利息 | 146.6万 USD | — | 132.8万 USD | 9000 USD | 2000 USD |
| 減価償却費と償却費 | 5.3万 USD | 1万 USD | 6000 USD | 4000 USD | 4000 USD |
| 営業利益 | −3859.9万 USD | −6207.4万 USD | −1056.3万 USD | 1822.6万 USD | −2270.5万 USD |
| 純利益 | −4959.1万 USD | −5753.2万 USD | −998.6万 USD | 1788.8万 USD | −5669.3万 USD |
会社概要が更新されました 2026年10月10日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM812.33万0.01%782.66億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI810.66万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 Growth ETFIWO283.55万0.02%139.72億 USD0.24%$356.78+0.94%
Vanguard Extended Market ETFVXF236.12万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO111.68万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC98.39万0.07%13.17億 USD0.60%$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC41.34万0.04%10.45億 USD0.20%$86.29+0.43%
Fidelity Enhanced Small Cap ETFFESM38.16万0.01%64.1億 USD0.28%$45.46+0.46%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
